Research Blogs
Tried Antidepressants? How TMS Fits In
TMS is being studied for Alzheimer’s and mild cognitive impairment, with some encouraging results. An honest look at the brain targets, the treatment schedules, why age changes the dose, and what TMS can and cannot do. Estimated read time: about 11 minutes.
The THREE-D Trial – iTBS Non-Inferior to Standard rTMS for Depression (Blumberger et al. 2018)
The THREE-D Trial – iTBS Non-Inferior to Standard rTMS for Depression (Blumberger et al. 2018) What this study was Who was studied What the protocol involved What the results showed What it means and what it doesn’t Why this study matters for patients What this study was The THREE-D trial is the largest randomized controlled trial comparing intermittent theta burst stimulation to standard high-frequency rTMS for major depressive disorder. It was a non-inferiority trial, meaning its primary question was not whether iTBS was better than rTMS, but whether it was at least as good. It was conducted across multiple Canadian
D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation for Major Depressive Disorder (Cole, Sohn et al., 2022)
D-Cycloserine Augmentation of Intermittent Theta Burst Stimulation for Major Depressive Disorder (Cole, Sohn et al., 2022) What this study was Who was studied What the protocol involved What the results showed What it means — and what it doesn’t Why this study matters for patients What this study was This was a randomized, double-blind, placebo-controlled clinical trial evaluating whether D-cycloserine a partial NMDA receptor agonist improves the antidepressant effects of intermittent theta burst stimulation when administered immediately before each TMS session. It was conducted at the University of Calgary and published in JAMA Psychiatry in 2022 by Cole, Sohn, McGirr
Ready to learn if TMS is right for you?
A brief conversation is all it takes. No pressure, no commitment – just clarity.